ATE528396T1 - Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften - Google Patents
Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaftenInfo
- Publication number
- ATE528396T1 ATE528396T1 AT05809866T AT05809866T ATE528396T1 AT E528396 T1 ATE528396 T1 AT E528396T1 AT 05809866 T AT05809866 T AT 05809866T AT 05809866 T AT05809866 T AT 05809866T AT E528396 T1 ATE528396 T1 AT E528396T1
- Authority
- AT
- Austria
- Prior art keywords
- polypeptide
- amino acids
- mutagenesis
- libraries
- look
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58591804P | 2004-07-06 | 2004-07-06 | |
| PCT/US2005/024140 WO2006023144A2 (en) | 2004-07-06 | 2005-07-06 | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE528396T1 true ATE528396T1 (de) | 2011-10-15 |
Family
ID=35968026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05809866T ATE528396T1 (de) | 2004-07-06 | 2005-07-06 | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9012369B2 (de) |
| EP (1) | EP1774019B1 (de) |
| JP (2) | JP4939410B2 (de) |
| AT (1) | ATE528396T1 (de) |
| BR (1) | BRPI0513155B1 (de) |
| CA (1) | CA2572917C (de) |
| ES (1) | ES2372503T3 (de) |
| MX (1) | MX2007000105A (de) |
| WO (1) | WO2006023144A2 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
| WO2007127290A2 (en) * | 2006-04-24 | 2007-11-08 | Protelix, Inc. | Method for producing viral vaccine and therapeutic peptide antigens |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US20090118130A1 (en) | 2007-02-12 | 2009-05-07 | Codexis, Inc. | Structure-activity relationships |
| US8372619B2 (en) * | 2007-07-12 | 2013-02-12 | New England Biolabs, Inc. | High fidelity restriction endonucleases |
| KR101561314B1 (ko) * | 2007-09-26 | 2015-10-16 | 추가이 세이야쿠 가부시키가이샤 | 항ｉｌ－６ 수용체 항체 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CN101874041B (zh) | 2007-09-26 | 2013-06-19 | 中外制药株式会社 | 抗体恒定区修饰体 |
| AU2008328784B2 (en) | 2007-11-27 | 2014-03-27 | Ablynx N.V. | Immunoglobulin constructs |
| WO2009088933A1 (en) * | 2007-12-31 | 2009-07-16 | Xoma Technology Ltd. | Methods and materials for targeted mutagenesis |
| DK2275443T3 (en) | 2008-04-11 | 2016-02-08 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repetitively binding to two or more antigen molecules |
| AU2009242038B2 (en) | 2008-05-02 | 2013-05-30 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| WO2010111707A1 (en) | 2009-03-27 | 2010-09-30 | Sapphire Energy, Inc. | Variant isoprenoid producing enzymes and uses thereof |
| AU2010233658B2 (en) | 2009-04-10 | 2013-11-28 | Ablynx Nv | Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders |
| EP2417162A2 (de) | 2009-04-10 | 2012-02-15 | Ablynx N.V. | Verbesserte, gegen il-6r gerichtete amiinosäuresequenzen und polypeptide, die diese enthalten, zur behandlung von krankheiten und erkrankungen, die mit il-6r in zusammenhang stehen |
| ES2643034T3 (es) | 2009-06-05 | 2017-11-21 | Ablynx N.V. | Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| EP3248987A1 (de) | 2010-07-30 | 2017-11-29 | Novartis AG | Fibronectin-cradle-moleküle und bibliotheken |
| MX360946B (es) * | 2010-09-22 | 2018-10-29 | Amgen Inc Star | Inmunoglobulinas portadoras y usos de las mismas. |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| US10138302B2 (en) | 2011-09-23 | 2018-11-27 | Ablynx N.V. | Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies |
| RU2704992C2 (ru) | 2011-10-11 | 2019-11-01 | МЕДИММЬЮН, ЭлЭлСи | CD40L-СПЕЦИФИЧНЫЕ КАРКАСНЫЕ СТРУКТУРЫ, ПРОИСХОДЯЩИЕ ИЗ Tn3, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| RU2014139911A (ru) | 2012-03-02 | 2016-04-20 | Аблинкс Нв | Антитела из одиночных вариабельных доменов, связывающие белок pcrv pseudomonas aeruginosa |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| WO2014116051A1 (ko) | 2013-01-24 | 2014-07-31 | 스크립스코리아 항체연구원 | 단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법 |
| US9896685B2 (en) | 2013-04-25 | 2018-02-20 | Sutro Biopharma, Inc. | Use of LAMBDA-GAM protein in ribosomal display technology |
| DK2989239T3 (en) * | 2013-04-25 | 2018-09-03 | Sutro Biopharma Inc | Selection of Fab fragments using ribosome display technology |
| WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| KR102207770B1 (ko) | 2013-08-05 | 2021-01-26 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 유전자 라이브러리 |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| WO2016062766A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| RU2730590C2 (ru) | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Композиция для лечения заболеваний, связанных с ил-6 |
| EP3268389B1 (de) | 2015-03-12 | 2020-09-30 | Medimmune, LLC | Verfahren zur aufreinigung von albuminfusionsproteinen |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| PL3299810T3 (pl) | 2015-05-19 | 2021-12-13 | National Center Of Neurology And Psychiatry | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) |
| JP6867302B2 (ja) | 2015-05-21 | 2021-04-28 | フル スペクトラム ジェネティクス， インコーポレイテッド | タンパク質の特徴を改善する方法 |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| CN108603307A (zh) | 2015-12-01 | 2018-09-28 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| USD782516S1 (en) | 2016-01-19 | 2017-03-28 | Apple Inc. | Display screen or portion thereof with graphical user interface |
| KR102212257B1 (ko) | 2016-08-22 | 2021-02-04 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 핵산 라이브러리 |
| KR102217487B1 (ko) | 2016-09-21 | 2021-02-23 | 트위스트 바이오사이언스 코포레이션 | 핵산 기반 데이터 저장 |
| GB2573069A (en) | 2016-12-16 | 2019-10-23 | Twist Bioscience Corp | Variant libraries of the immunological synapse and synthesis thereof |
| KR20190119107A (ko) | 2017-02-22 | 2019-10-21 | 트위스트 바이오사이언스 코포레이션 | 핵산 기반 데이터 저장 |
| EP3595674A4 (de) | 2017-03-15 | 2020-12-16 | Twist Bioscience Corporation | Variante bibliotheken der immunologischen synapse und synthese davon |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| AU2018284227B2 (en) | 2017-06-12 | 2024-05-02 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| SG11202002194UA (en) | 2017-09-11 | 2020-04-29 | Twist Bioscience Corp | Gpcr binding proteins and synthesis thereof |
| EP3697529B1 (de) | 2017-10-20 | 2023-05-24 | Twist Bioscience Corporation | Beheizte nanowells für polynukleotidsynthese |
| KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
| SG11202006460SA (en) | 2018-01-04 | 2020-08-28 | Twist Bioscience Corp | Dna-based digital information storage |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| SG11202109283UA (en) | 2019-02-26 | 2021-09-29 | Twist Bioscience Corp | Variant nucleic acid libraries for antibody optimization |
| KR20210143766A (ko) | 2019-02-26 | 2021-11-29 | 트위스트 바이오사이언스 코포레이션 | Glp1 수용체에 대한 변이체 핵산 라이브러리 |
| CN114729342A (zh) | 2019-06-21 | 2022-07-08 | 特韦斯特生物科学公司 | 基于条形码的核酸序列装配 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69112207T2 (de) * | 1990-04-05 | 1996-03-28 | Roberto Chestnut Hill Mass. Crea | "walk-through"-mutagenese. |
| AU1456101A (en) * | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
| AU784983B2 (en) * | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| WO2003089671A1 (en) * | 2002-04-17 | 2003-10-30 | Roberto Crea | 'doping' in walk-through mutagenesis |
| CN1653335A (zh) * | 2002-04-17 | 2005-08-10 | 罗伯特欧·克瑞 | 免疫球蛋白通用文库 |
| RU2005140664A (ru) * | 2003-06-27 | 2007-08-27 | Байорен, Инк. (Us) | Просматривающий мутагенез |
-
2005
- 2005-07-06 WO PCT/US2005/024140 patent/WO2006023144A2/en active Application Filing
- 2005-07-06 BR BRPI0513155-3A patent/BRPI0513155B1/pt active IP Right Grant
- 2005-07-06 JP JP2007520506A patent/JP4939410B2/ja active Active
- 2005-07-06 ES ES05809866T patent/ES2372503T3/es active Active
- 2005-07-06 US US11/571,088 patent/US9012369B2/en active Active
- 2005-07-06 AT AT05809866T patent/ATE528396T1/de not_active IP Right Cessation
- 2005-07-06 EP EP05809866A patent/EP1774019B1/de active Active
- 2005-07-06 MX MX2007000105A patent/MX2007000105A/es active IP Right Grant
- 2005-07-06 CA CA2572917A patent/CA2572917C/en active Active
-
2011
- 2011-09-15 JP JP2011201518A patent/JP2012041347A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2572917A1 (en) | 2006-03-02 |
| JP4939410B2 (ja) | 2012-05-23 |
| US20080214406A1 (en) | 2008-09-04 |
| EP1774019A4 (de) | 2009-05-20 |
| JP2012041347A (ja) | 2012-03-01 |
| CA2572917C (en) | 2012-04-03 |
| US9012369B2 (en) | 2015-04-21 |
| BRPI0513155A (pt) | 2008-04-29 |
| BRPI0513155B1 (pt) | 2021-07-20 |
| WO2006023144A2 (en) | 2006-03-02 |
| JP2008505642A (ja) | 2008-02-28 |
| ES2372503T3 (es) | 2012-01-20 |
| EP1774019A2 (de) | 2007-04-18 |
| MX2007000105A (es) | 2007-07-18 |
| EP1774019B1 (de) | 2011-10-12 |
| WO2006023144A3 (en) | 2006-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE528396T1 (de) | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften | |
| WO2005003345A3 (en) | Look-through mutagenesis | |
| ES2078518T3 (es) | Mutagenesis por desplazamiento completo. | |
| Tu et al. | Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion | |
| Camporeale et al. | K8 and K12 are biotinylated in human histone H4 | |
| Jirácek et al. | Development of Highly Potent and Selective Phosphinic Peptide Inhibitors of Zinc Endopeptidase 24-15 Using Combinatorial Chemistry (∗) | |
| Lai et al. | The emerging role of the peptidome in biomarker discovery and degradome profiling | |
| Schroeter et al. | Bone protein “extractomics”: comparing the efficiency of bone protein extractions of Gallus gallus in tandem mass spectrometry, with an eye towards paleoproteomics | |
| WO2003099999A3 (en) | Generation and selection of protein library in silico | |
| ATE344456T1 (de) | Durch affinität ausgewählte unterschriftspeptide zur identifizierung und quantifizierung von proteinen | |
| ATE437364T1 (de) | Detektion von peptiden | |
| CN105277712B (zh) | 一种鉴定赖氨酸ε‑氨基侧链单甲基化修饰的方法 | |
| WO2002042427A3 (en) | Mass tags for quantitative analysis | |
| DE60109490D1 (de) | Umgekehrtes labelierungsverfahren zur schnellen identifikation von marker/ziel-proteinen | |
| JP2019507341A5 (de) | ||
| Fu et al. | rMCP-2, the major rat mucosal mast cell protease, an analysis of its extended cleavage specificity and its potential role in regulating intestinal permeability by the cleavage of cell adhesion and junction proteins | |
| Slagboom et al. | Analytical strategies in venomics | |
| DE69114339D1 (de) | Verfahren zur Identifizierung oder Bestimmung von Proteinen und Verwendungen dazu. | |
| ATE223971T1 (de) | Neue methoden zum auffinden von liganden- und ziel-biomolekülen | |
| ATE288589T1 (de) | Verfahren zur analyse von proteinen | |
| SE0302559D0 (sv) | Method | |
| Jurgilas et al. | PO41, a snake venom metalloproteinase inhibitor isolated from Philander opossum serum | |
| WO2008142664A3 (en) | Exposed thymidine kinase 1 peptides, ligands and methods employing the same | |
| Tong et al. | Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor | |
| WO2005005990A3 (en) | Inverse labeling method for the rapid identification of marker target proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |